Are you particular about the "freezing method" of pharmaceutical raw materials? It is possible to freeze and thaw raw materials more safely and securely while maintaining quality!
Of the biopharmaceutical active ingredients, 59.4% are transported in a frozen state. Therefore, the development of controllable and efficient freezing and thawing technologies is increasingly in demand. For example, in the development of COVID-19 vaccines, there has been a growing emphasis on storage and transportation methods, highlighting the necessity for these solutions. Recently, the combination of Allegro BioContainers and RoSS Technology has resulted in the development of an excellent active ingredient management solution through synergistic effects. It allows for the control of frozen active ingredients between the purification process and the formulation and filling processes, enabling stable and safe storage and transportation. Additionally, it prevents losses of active ingredients due to the breakage of frozen single-use packs, bringing the risk of loss close to 0%.
Inquire About This Product
basic information
Freeze, Storage, Transportation, and Thawing Platform for Biopharmaceutical Active Ingredients By combining the Allegro Biocontainer, a single-use bag, with the RoSS shell and the freeze-thaw platform, we can safely, securely, and stably manage biopharmaceutical active ingredients in a frozen state, maintaining the quality and activity of the active ingredients. 【Features】 ■ Robust protection for single-use bags ■ Reduced footprint through high-density storage ■ Quality control through advanced temperature management ■ Reduction of losses of active ingredients due to leaks or damage *For more details, please feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
End-to-end solution for freezing, storing, transporting, and thawing biopharmaceutical active ingredients ■ Purification process ■ Formulation and filling process etc.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
![[CPhI Seminar Report] Mutagenic Impurities in Pharmaceuticals (Active Pharmaceutical Ingredients)](https://image.mono.ipros.com/public/product/image/86f/2000714763/IPROS54094091646706511898.png?w=280&h=280)
